April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a Phase II Clinical Trial of ...

CEO Richard A. Miller stated the company's main focus remains the development of soquelitinib for atopic dermatitis, highlighting "an oral medication featuring a novel mechanism of action that so far ...

Affinia Therapeutics has received approval from Health Canada for its clinical trial application (CTA) to begin the UPBEAT ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

NanoViricides (NYSE-A:NNVC) said on Wednesday it expects to begin a Phase II clinical trial of its antiviral candidate NV-387 ...

First patient dosed in France, expanding the DOMISOL study beyond AustraliaDT‑7012 is being evaluated as monotherapy and in ...

A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

The DPP1 inhibitor did not beat placebo in this trial, leaving branded Bimzelx and Cosentyx, as well as Humira and its ...

Prediction of Treatment Efficacy in Locally Advanced Rectal Cancer Using a Clinical and Magnetic Resonance Imaging–Based Radiomics-Immunological Model for Total Neoadjuvant Therapy Fifty patients were ...

Management outlined plans to initiate the Phase II trial for soquelitinib in atopic dermatitis before year-end, with enrollment of approximately 200 patients. The treatment period is set for 12 weeks, ...